Browsing Tag
United States
1091 posts
H2 Global Group enters growth phase with hydrogen therapy for Alzheimer’s and neurodegenerative diseases
H2 Global Group eyes EU and FDA milestones as it advances hydrogen therapy for Alzheimer’s and projects $48M revenues by 2029—read the in-depth analysis.
Union Pacific climbs to the top of industrials as Axon Enterprise stumbles
Union Pacific (NYSE: UNP) stock rallied while Axon Enterprise (NASDAQ: AXON) fell—discover what drove the industrials divergence and what investors expect next.
Trump, Palestine, and Petro: How one speech led Washington to revoke a head of state’s visa
The U.S. revoked Colombian president Gustavo Petro’s visa after a Gaza protest speech. Explore what it means for U.S.–Colombia ties and global diplomacy.
Canada to woo U.S. H-1B holders with new immigration offer as Carney outlines strategy
Canada eyes U.S. H-1B visa holders with a new offer as PM Carney promises swift action. Find out how this move could reshape global tech talent flows.
Why Merck’s MSD is paying up to $600m for Evaxion’s undisclosed vaccine candidate EVX-B3
MSD licenses Evaxion’s AI-discovered vaccine EVX-B3 with $7.5M upfront and up to $592M in milestones—why this risky biotech bet could redefine vaccines.
Trump strikes $14bn TikTok deal: Can US investor control secure the app’s future?
Trump’s deal puts TikTok under U.S. investor control in a $14B restructuring. Find out what it means for users, investors, and digital sovereignty today.
Trump’s 100% tariff on branded pharmaceuticals without U.S. plants shocks global drugmakers
Trump’s 100% tariff on branded drugs without U.S. plants could double costs, disrupt supplies, and reshape global pharma strategies. Read what’s at stake.
The global transformer crunch: Why this hidden bottleneck could stall the energy transition
Transformer shortages are emerging as a critical bottleneck in the energy transition. Find out why demand is surging and how it could reshape global grids.
Is pharma nationalism reshaping global R&D? What GSK, Eli Lilly, and AstraZeneca are signaling to the world
GSK, Eli Lilly and AstraZeneca are reshaping global pharma strategy with massive U.S. investments—find out what this means for R&D, supply chains, and policy.
Aramco’s green retreat: What the failed Repsol deal reveals about Big Oil’s future
Aramco paused a €1B bid for Repsol’s renewables unit. Learn why talks stalled, what it means for valuations, and how investors should respond.